0001144204-17-047843.txt : 20170913 0001144204-17-047843.hdr.sgml : 20170913 20170913160330 ACCESSION NUMBER: 0001144204-17-047843 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170908 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20170913 DATE AS OF CHANGE: 20170913 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cellectar Biosciences, Inc. CENTRAL INDEX KEY: 0001279704 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043321804 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36598 FILM NUMBER: 171083226 BUSINESS ADDRESS: STREET 1: 3301 AGRICULTURE DRIVE CITY: MADISON STATE: WI ZIP: 53716 BUSINESS PHONE: (608) 441-8120 MAIL ADDRESS: STREET 1: 3301 AGRICULTURE DRIVE CITY: MADISON STATE: WI ZIP: 53716 FORMER COMPANY: FORMER CONFORMED NAME: NOVELOS THERAPEUTICS, INC. DATE OF NAME CHANGE: 20050617 FORMER COMPANY: FORMER CONFORMED NAME: COMMON HORIZONS INC DATE OF NAME CHANGE: 20040211 8-K 1 v475105_8k.htm FORM 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

___________________

FORM 8-K

___________________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: September 8, 2017
(Date of earliest event reported)

CELLECTAR BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)

Delaware

1-36598

04-3321804

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification Number)

3301 Agriculture Drive, Madison, Wisconsin 53716
(Address of principal executive offices)

(608) 441-8120
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

ITEM 7.01

REGULATION FD DISCLOSURE

On September 8, 2017, the University of Wisconsin School of Medicine and Health issued a press release announcing that the University of Wisconsin Carbone Cancer Center published a study in the Journal of Nuclear Medicine finding that Cellectar Biosciences, Inc.’s lead compound, CLR 131, could become the first targeted, molecular radiotherapy to be tested in clinical trials that treats a broad variety of solid tumors in children. The press release can be found at the following URL address: http://www.med.wisc.edu/news-events/clr-131-found-to-broadly-target-pediatric-solid-tumors/51323.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 13, 2017

CELLECTAR BIOSCIENCES, INC.

/s/ John P. Hamill

John P. Hamill

Interim Chief Financial Officer